title: A novel nano drug delivery system based on tigecycline-loaded calciumphosphate coated with poly-DL-lactide-co-glycolide.
abstract: The purpose of the study presented in this paper has been to examine the possibility of the synthesis of a new nanoparticulate system for controlled and systemic drug delivery with double effect. In the first step, a drug is released from bioresorbable polymer; in the second stage, after resorption of the polymer, non-bioresorbable calcium phosphate remains the chief part of the particle and takes the role of a filler, filling a bone defect. The obtained tigecycline-loaded calcium-phosphate(CP)/poly(DL-lactide-co-glycolide)(PLGA) nanoparticles contain calcium phosphate coated with bioresorbable polymer. The composite was analyzed by FT-IR, XRD and AFM methods. The average particle size of the nanocomposite ranges between 65 and 95 nm. Release profiles of tigecycline were obtained by UV-VIS spectroscopy in physiological solution at 37 degrees C. Experimental results were analyzed using Peppas and Weibull mathematical models. Based on kinetic parameters, tigecycline release was defined as non-Fickian transport. The cytotoxicity of the nanocomposite was examined on standard cell lines of MC3T3-E1, in vitro. The obtained low values of lactate dehydrogenase (LDH) activity (under 37%) indicate low cytotoxicity level. The behaviour of the composite under real-life conditions was analyzed through implantation of the nanocomposite into living organisms, in vivo. The system with the lowest tigecycline content proved to be an adequate system for local and controlled release. Having in mind the registered antibiotics concentration in other tissues, delivery systems with a higher tigecycline content show both local and systemic effects.
authors.affiliation: Institute of Technical Sciences of the Serbian Academy of Sciences and Arts, Belgrade, Serbia.
authors.forename: Nenad L
authors.initials: NL
authors.lastname: Ignjatović
authors.forename: Petar
authors.initials: P
authors.lastname: Ninkov
authors.forename: Roya
authors.initials: R
authors.lastname: Sabetrasekh
authors.forename: Dragan P
authors.initials: DP
authors.lastname: Uskoković
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics; D002130:Calcium Phosphates / Q000737:chemistry*; D002478:Cells, Cultured; D020099:Coated Materials, Biocompatible / Q000138:chemical synthesis / Q000737:chemistry / Q000493:pharmacokinetics; D004337:Drug Carriers; D016503:Drug Delivery Systems; D004343:Drug Implants; D006801:Humans; D019344:Lactic Acid / Q000737:chemistry*; D008422:Materials Testing; D008911:Minocycline / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D008954:Models, Biological; D049329:Nanostructures / Q000737:chemistry*; D010316:Particle Size; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D051381:Rats; D000078304:Tigecycline
chemical_list: D000900:Anti-Bacterial Agents; D002130:Calcium Phosphates; D020099:Coated Materials, Biocompatible; D004337:Drug Carriers; D004343:Drug Implants; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D000078304:Tigecycline; C020243:calcium phosphate; D008911:Minocycline
references.citation: J Tissue Eng Regen Med. 2007 Jan-Feb;1(1):4-24
references.pmid: 18038388
references.citation: J Biomater Appl. 2007 Jan;21(3):317-28
references.pmid: 17229816
references.citation: Intensive Crit Care Nurs. 2008 Aug;24(4):260-3
references.pmid: 18554910
references.citation: Biomaterials. 2008 Jan;29(3):350-8
references.pmid: 17977596
references.citation: Adv Dent Res. 1998 Nov;12(2):136-43
references.pmid: 9972138
references.citation: Ultrason Sonochem. 2008 Jan;15(1):16-20
references.pmid: 17845864
references.citation: Biomaterials. 2006 Aug;27(23):4239-49
references.pmid: 16620958
references.citation: J Biochem Mol Biol. 2007 Nov 30;40(6):881-7
references.pmid: 18047782
references.citation: Biomaterials. 2005 May;26(13):1553-63
references.pmid: 15522757
references.citation: J Mater Sci Mater Med. 2005 Jul;16(7):621-6
references.pmid: 15965593
references.citation: Acta Biomater. 2005 Jan;1(1):65-83
references.pmid: 16701781
references.citation: Biomaterials. 2003 Mar;24(7):1213-21
references.pmid: 12527262
references.citation: Acta Biomater. 2008 Sep;4(5):1480-6
references.pmid: 18485844
references.citation: J Control Release. 2014 Sep 28;190:31-2
references.pmid: 25356469
references.citation: Science. 1990 Mar 23;247(4949):1439-45
references.pmid: 17791211
references.citation: Biomaterials. 2001 May;22(9):897-901
references.pmid: 11311008
references.citation: Drug Deliv. 2007 Aug;14(6):349-56
references.pmid: 17701524
references.citation: Int J Pharm. 2007 May 4;336(1):75-81
references.pmid: 17174495
references.citation: J Control Release. 2008 Apr 21;127(2):146-53
references.pmid: 18325617
references.citation: Acta Biomater. 2007 Nov;3(6):927-35
references.pmid: 17532275
references.citation: J Mater Sci Mater Med. 2003 Mar;14(3):201-9
references.pmid: 15348465
references.citation: Int J Pharm. 2008 Dec 8;364(2):328-43
references.pmid: 18822362
references.citation: Microsc Res Tech. 2006 Dec;69(12):976-82
references.pmid: 17013913
references.citation: Colloids Surf B Biointerfaces. 2007 Oct 1;59(2):215-23
references.pmid: 17596919
references.citation: Biomaterials. 2006 Sep;27(26):4635-45
references.pmid: 16716395
references.citation: J Control Release. 2004 Sep 14;99(1):41-52
references.pmid: 15342179
references.citation: Biomaterials. 2002 Mar;23(6):1411-6
references.pmid: 11829436
references.citation: J Antimicrob Chemother. 2001 Jun;47(6):885-91
references.pmid: 11389124
references.citation: Clin Infect Dis. 2004 Apr 15;38(8):1049-55
references.pmid: 15095205
references.citation: J Biomed Biotechnol. 2007;2007(7):84965
references.pmid: 18273414
references.citation: Int J Pharm. 2004 Apr 15;274(1-2):261-8
references.pmid: 15072801